Elicio Therapeutics announced updated data from its ELI-002 Phase 1 AMPLIFY-7P study at a cancer conference, highlighting T cell and disease-free survival improvements.
AI Assistant
ELICIO THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.